Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia

Trial Profile

Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Nov 2011 Interim results published in Haematologica.
    • 18 Dec 2006 Status change
    • 13 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top